Latest news with #Viehbacher
Boston Globe
7 days ago
- Health
- Boston Globe
Biogen sees potential in combining Alzheimer's and obesity drugs
Advertisement Biogen's looking to the growth of its Alzheimer's drug Leqembi to offset the decline of its multiple sclerosis franchise, which is facing competition from cheaper generic drugs. Biogen's new Alzheimer's drug is already facing competition from Eli Lilly & Co.'s Alzheimer's drug, which was approved in the US last year and has since captured around 30 percent of the market, according to analysts. Other companies are also circling. Novo is carrying out clinical trials to assess whether the main ingredient in diabetes drug Ozempic and weight-loss shot Wegovy might help people with early Alzheimer's disease. Research suggests that the weight-loss drug could slow Alzheimer's progression by impacting inflammation and vascular health. Results of Novo's late-stage trial are expected later this year. Advertisement Viehbacher noted that being overweight is a risk factor for Alzheimer's. He cautioned the Novo study 'is a fairly risky proposition,' adding that 'most of the experts we're talking to are not convinced that it will work.' 'It's logical if you have a weight-loss drug that you can see some benefit, but it's actually pretty hard to move the needle on the cognitive side,' Viehbacher added. Alzheimer's drug development has been riddled with failures, even when drugs looked promising in early studies. Leqembi is a partnership between Cambridge, Massachusetts-based Biogen and Japanese drugmaker Eisai Co. Biogen makes the active ingredient for Leqembi in Switzerland. The company then ships it to North Carolina, where it gets made into a product. President Donald Trump recently put a 39 percent tariff on imports from Switzerland. It's unclear whether this would impact Biogen's drug. Still, Viehbacher said the company has the ability to start producing the substance used to make Leqembi in North Carolina for the US market, while continuing to make it in Switzerland for outside the US. He said the company always intended to use its North Carolina facilities to make Leqembi and the potential move was not a direct response to Trump's tariff threats. Last month, Biogen announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park.
Mint
7 days ago
- Health
- Mint
Biogen Sees Potential in Combining Alzheimer's and Obesity Drugs
(Bloomberg) -- If Novo Nordisk A/S's wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer's disease, Biogen Inc.'s Chief Executive Officer Chris Viehbacher doesn't see it as a roadblock for his company's medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy. 'As we look out over the next five years, we're probably going to see a treatment much like any other complex disease,' he said in an interview with Bloomberg News, meaning there will be 'different mechanisms of action that you need.' It's not uncommon for drugmakers to study combinations of treatments when two seem to work for the same condition, in hope of boosting the benefit. Viehbacher said if Novo's study works, Biogen 'might' do trials looking at the two drugs in combination but cautioned the timeline might not make sense given Alzheimer's studies take years to complete. Biogen's looking to the growth of its Alzheimer's drug Leqembi to offset the decline of its multiple sclerosis franchise, which is facing competition from cheaper generic drugs. Biogen's new Alzheimer's drug is already facing competition from Eli Lilly & Co.'s Alzheimer's drug, which was approved in the US last year and has since captured around 30% of the market, according to analysts. Other companies are also circling. Novo is carrying out clinical trials to assess whether the main ingredient in diabetes drug Ozempic and weight-loss shot Wegovy might help people with early Alzheimer's disease. Research suggests that the weight-loss drug could slow Alzheimer's progression by impacting inflammation and vascular health. Results of Novo's late-stage trial are expected later this year. Viehbacher noted that being overweight is a risk factor for Alzheimer's. He cautioned the Novo study 'is a fairly risky proposition,' adding that 'most of the experts we're talking to are not convinced that it will work.' 'It's logical if you have a weight-loss drug that you can see some benefit, but it's actually pretty hard to move the needle on the cognitive side,' Viehbacher added. Alzheimer's drug development has been riddled with failures, even when drugs looked promising in early studies. Leqembi is a partnership between Cambridge, Massachusetts-based Biogen and Japanese drugmaker Eisai Co. Biogen makes the active ingredient for Leqembi in Switzerland. The company then ships it to North Carolina, where it gets made into a product. President Donald Trump recently put a 39% tariff on imports from Switzerland. It's unclear whether this would impact Biogen's drug. Still, Viehbacher said the company has the ability to start producing the substance used to make Leqembi in North Carolina for the US market, while continuing to make it in Switzerland for outside the US. He said the company always intended to use its North Carolina facilities to make Leqembi and the potential move was not a direct response to Trump's tariff threats. Last month, Biogen announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park. More stories like this are available on
Yahoo
12-02-2025
- Business
- Yahoo
Drugmaker Biogen forecasts 2025 profit below expectations
(Reuters) - Biogen (BIIB) forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis. Biogen stock fell 3% in pre-market trading on Wednesday. Investors sold Biogen shares in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's Eisai, exacerbated worries of slowing sales growth. The company in 2022 hired as its top boss former Sanofi CEO Christopher Viehbacher, who launched a $1 billion cost-savings plan and entered deals such as its $6.5 billion acquisition of Reata Pharmaceuticals in 2023. Biogen expects 2025 revenue to decline by a mid-single digit percentage, excluding the impact of currency fluctuations, from 2024 levels. "Our financial discipline has enabled a restructuring of our operating expenses with a reallocation of resources toward potential future growth drivers," CEO Viehbacher said. On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts had forecast 2025 profit of $16.34 per share. The outlook does not include any impact from either potential acquisitions or tax and healthcare reforms, as all are hard to predict, the company said. Excluding certain items, Biogen earned $3.44 per share in the fourth quarter ended December 31, compared with estimates of $3.35.
Reuters
12-02-2025
- Business
- Reuters
Drugmaker Biogen forecasts 2025 profit below expectations
Feb 12 (Reuters) - Biogen (BIIB.O), opens new tab forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis. Investors sold Biogen shares in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's Eisai (4523.T), opens new tab, exacerbated worries of slowing sales growth. The company in 2022 hired as its top boss former Sanofi CEO Christopher Viehbacher, who launched a $1 billion cost-savings plan and entered deals such as its $6.5 billion acquisition of Reata Pharmaceuticals in 2023. Biogen expects 2025 revenue to decline by a mid-single digit percentage, excluding the impact of currency fluctuations, from 2024 levels. "Our financial discipline has enabled a restructuring of our operating expenses with a reallocation of resources toward potential future growth drivers," CEO Viehbacher said. On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts had forecast 2025 profit of $16.34 per share. The outlook does not include any impact from either potential acquisitions or tax and healthcare reforms, as all are hard to predict, the company said. Excluding certain items, Biogen earned $3.44 per share in the fourth quarter ended December 31, compared with estimates of $3.35. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
